The NIHR Horizon Scanning Research and Intelligence Centre has published a horizon scanning review of new technologies that are being developed for the diagnosis, treatment and management of epilepsy. Epilepsy is a common neurological condition that affects around 600,000 people in the UK (equivalent to almost 1 in 100 people). It causes sudden and unprovoked seizures (fits) that start in the brain. There are over 40 different types of epilepsy, and although the condition can start at any age, it is most commonly diagnosed in people under the age of 20 years.
This report provides an overview of 114 new tests and treatments that are being developed to improve the future diagnosis and management of this important condition. Researchers are making exciting advances across a wide range of technology areas, including anti-epileptic drugs, neurostimulation devices, imaging and genetic techniques, as well as new surgical, digital and cognitive technologies.
Lacosamide is a medicinal product that is being developed for the treatment of Primary Generalised Tonic-Clonic Seizures (PGTCS). Epilepsy is a neurological disorder that is characterised by an imbalance in the excitation and inhibition of the brain and this imbalance causes a phenomenon known as a seizure. Seizures are brief increases in electrical activity within …